secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-197008
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen shareholders elect directors and approve compensation policy and equity plan amendment at 2024 annual meeting
--------------------------------------------------------------------------------

- All eight director nominees elected with over 24M votes for each; broker non-votes 6.75M.
- 2024 Compensation Policy approved: 22.4M for, 3.4M against, 513K abstentions, 6.75M broker non-votes.
- Amendment to 2017 Equity Plan adding 800K shares approved: 22.7M for, 3.1M against, 548K abstentions.
- Advisory vote on named executive officer compensation passed: 22.6M for, 3.1M against, 553K abstentions.
- PricewaterhouseCoopers LLP ratified as auditor: 33.0M for, 8,345 against, 7,053 abstentions; no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524197008/0001193125-24-197008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524197008/d875882d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer